The Trump administration has withdrawn $766 million in funding previously awarded to Moderna Inc. for developing a vaccine targeting potential pandemic influenza viruses, including H5N1 bird flu. This decision was communicated on a Wednesday, leading to uncertainty over the project's future. Despite this setback, Moderna reported positive interim results from its vaccine trial involving 300 healthy adults, indicating a promising immune response. The lost funding would have been crucial for late-stage trials intended to assess the vaccine's efficacy against pandemic threats, including avian flu, which has already begun to affect human health in the U.S.
The Health and Human Services Department canceled $766 million in funding for Moderna's vaccine development for pandemic influenza, raising concerns over future preparedness.
Despite the funding cancellation, Moderna reported positive results from trials of its mRNA-1018 vaccine against H5 bird flu, indicating a robust immune response.
Collection
[
|
...
]